{"a":[{"_":"Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact","$":{"href":"/biotech/merck-moderna-cancer-vaccine-data-spur-speculation-keytruda-impact","hreflang":"en"}}]}
Phase 3positiveMerck-Moderna cancer vaccineKeytrudaPositive
AI Analysis
Summary
Merck and Moderna released positive phase 3 data for their cancer vaccine candidate, adding $45 billion to Moderna's market cap. Analysts are evaluating the potential breadth of the vaccine's use compared to Keytruda.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 data released; added $45 billion to Moderna's market cap
Importance:8/10
Sentiment:
0.80
oncologyvaccinephase 3partnershipstock movement
Read the original article
Published by FierceBiotech on August 20, 2026 9:25 AM